NCT07409415Completed
A Real-World Study on the Efficacy, Safety, and Quality of Life of Different Treatment Approaches for Post-Chemotherapy Neutropenia in Cancer Patients
Source: ClinicalTrials.gov · Last updated 13 Feb 2026
Brief summary (registry, in English)
This is a multi-center, retrospective + prospective, real-world observational study. It aims to investigate, through a relatively large sample size, the effectiveness and safety of different treatment approaches for preventing and managing neutropenia in cancer patients after chemotherapy. Additionally, it seeks to observe the impact of different treatment management models on the quality of life of cancer patients undergoing chemotherapy, so as to provide real-world evidence for selecting different treatment strategies for cancer patients after chemotherapy in the future.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 3000 (actual)
- First submitted
- 4 Jan 2026
- Start date
- 15 Feb 2024
- Primary completion date
- 30 Jun 2025
- Lead sponsor
- Huazhong University of Science and Technology
- Diseases
- Childhood cancers
- NCT number
- NCT07409415
What you commit to
- Study type: Observational
- Participants enrolled: 3000
- From 15 Feb 2024 to the primary completion date, 30 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have received systemic bone radiotherapy within 15 days.
- Patients who have experienced a significant infection within the two weeks prior to study entry.
Other illness
- Patients with psychiatric disorders.
- Patients with severe dysfunction of the liver, kidneys, heart, or lungs.
Other
- Patients with language or communication barriers.
- Patients with severe bone marrow suppression.
Who the study is looking for
- Patients diagnosed with non-myeloid malignant tumors (such as breast cancer, lung cancer, colorectal cancer, gynecological cancers, esophageal cancer, head and neck cancers) through imaging, histopathological examination, etc.
- Patients who have received at least two cycles of chemotherapy.
- Patients with a white blood cell (WBC) count \> 3.0 × 10⁹/L or an absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L before chemotherapy.
- Patients with osteosarcoma or lymphoid leukemia must be ≥ 14 years of age; patients with other cancer types must be ≥ 18 years of age.
- Patients who voluntarily agree to participate in this study.
- Patients who do not develop serious complications after chemotherapy.
Age in the registry: 14 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology Coordinator of this site? Confirm its status | Wuhan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.